- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||lampalizumab|
|Search PubMed titles||lampalizumab|
|Search PubMed titles/abstracts||lampalizumab|
|Lampalizumab is the Fab antigen binding domain of a humanized monoclonal antibody targeting complement factor D (CFD), the rate-limiting initiator of the alternative complement pathway (AP). The humanized antibody was produced based on a mouse monoclonal (MAb 166-32) [3,5].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.